CIK 0001590877
- Non-accelerated filer
- Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 471851754
- Phone
- +1 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- Open-market buys, last 90 days
- $949,381
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$949,381. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-02-15 | Mills Kenneth T. President and CEO | Sale | −3,522 | $47.30 | $167K | 254,066 |
| 2019-02-15 | Mills Kenneth T. President and CEO | Sale | −8,066 | $47.84 | $386K | 246,000 |
| 2019-02-14 | Mills Kenneth T. President and CEO | Exercise or conversion | +15,000 | $0.85 | $13K | 261,000 |
| 2019-02-14 | Mills Kenneth T. President and CEO | Exercise or conversion · Employee Stock Option (Right to Buy) | −15,000 | 174,670 | ||
| 2019-02-07 | Vasista Vittal Chief Financial Officer | Exercise or conversion | +120,000 | $0.85 | $102K | 242,283 |
| 2019-02-07 | Vasista Vittal Chief Financial Officer | Exercise or conversion · Employee Stock Option (Right to Buy) | −120,000 | 84,900 | ||
| 2019-02-05 | Simpson Curran SVP, Product Development & CTO | Exercise or conversion | +8,450 | $35.80 | $303K | 47,950 |
| 2019-02-05 | Simpson Curran SVP, Product Development & CTO | Exercise or conversion | +32,882 | $22.00 | $723K | 80,832 |
| 2019-02-05 | Simpson Curran SVP, Product Development & CTO | Exercise or conversion | +1,875 | $19.50 | $37K | 82,707 |
| 2019-02-05 | Simpson Curran SVP, Product Development & CTO | Exercise or conversion | +625 | $13.09 | $8K | 83,332 |
| 2019-02-05 | Simpson Curran SVP, Product Development & CTO | Sale | −43,832 | $50.08 | $2.2M | 39,500 |
| 2019-02-05 | Simpson Curran SVP, Product Development & CTO | Exercise or conversion · Stock Option (Right to Buy) | −8,450 | 46,550 | ||
| 2019-02-05 | Simpson Curran SVP, Product Development & CTO | Exercise or conversion · Stock Option (Right to Buy) | −32,882 | 43,219 | ||
| 2019-02-05 | Simpson Curran SVP, Product Development & CTO | Exercise or conversion · Stock Option (Right to Buy) | −1,875 | 15,000 | ||
| 2019-02-05 | Simpson Curran SVP, Product Development & CTO | Exercise or conversion · Stock Option (Right to Buy) | −625 | 2,708 | ||
| 2019-02-01 | Mills Kenneth T. President and CEO | Exercise or conversion | +45,000 | $0.85 | $38K | 246,000 |
| 2019-02-01 | Mills Kenneth T. President and CEO | Exercise or conversion · Employee Stock Option (Right to Buy) | −45,000 | 189,670 | ||
| 2019-01-15 | Mills Kenneth T. President and CEO | Sale | −11,860 | $43.70 | $518K | 204,140 |
| 2019-01-15 | Mills Kenneth T. President and CEO | Sale | −3,140 | $44.40 | $139K | 201,000 |
| 2019-01-03 | Christmas Patrick J. SVP, General Counsel | Grant or award · Stock Option (Right to Buy) | +45,000 | 45,000 |
Page 30 of 43 · 852 trades